Lexaria Bioscience (LEXX) EPS (Weighted Average and Diluted) (2011 - 2026)
Lexaria Bioscience's (LEXX) quarterly EPS (Weighted Average and Diluted) came in at -$0.06 in Q1 2026, up 60.0% year-on-year from -$0.04 in Q1 2025, and up 14.29% quarter-over-quarter from -$0.07 in Q4 2025.
Lexaria Bioscience (LEXX) EPS (Weighted Average and Diluted) (2011 - 2026) Analysis & Trends
Lexaria Bioscience has disclosed EPS (Weighted Average and Diluted) across 6 years of filings, most recently posting -$0.06 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.06, up 60.0% year-over-year; the trailing twelve-month figure through Feb 2026 was -$0.47 (up 20.34% YoY), and the FY2025 annual result was -$0.66, down 40.43% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.06 for Q1 2026 at Lexaria Bioscience, up from -$0.07 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.18 in Q3 2023 to a low of -$0.21 in Q2 2025.
- The 4-year median for EPS (Weighted Average and Diluted) is -$0.13 (2023), against an average of -$0.1.
- Across the five-year window, EPS (Weighted Average and Diluted) plunged 182.68% in 2024 and soared 60.0% in 2026, its largest moves.
- Lexaria Bioscience's EPS (Weighted Average and Diluted) stood at -$0.13 in 2023, then declined by 23.08% to -$0.16 in 2024, then surged by 56.25% to -$0.07 in 2025, then rose by 14.29% to -$0.06 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.06 (Q1 2026), -$0.07 (Q4 2025), and -$0.13 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 | -0.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -0.06 |
| Nov 30, 2025 | -0.07 |
| Aug 31, 2025 | -0.13 |
| May 31, 2025 | -0.21 |
| Feb 28, 2025 | -0.15 |
| Nov 30, 2024 | -0.16 |
| Aug 31, 2024 | -0.15 |
| May 31, 2024 | -0.13 |
| Feb 29, 2024 | -0.06 |
| Nov 30, 2023 | -0.13 |
| Aug 31, 2023 | 0.18 |
| Apr 30, 2012 | -0.01 |
| Jan 31, 2012 | -0.01 |
| Jul 31, 2011 | -0.02 |
| Apr 30, 2011 | -0.01 |
| Jan 31, 2011 | -0.01 |